2015 Press Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012
DateTitle 
08/04/15Isis Reports Financial Results And Highlights For Second Quarter 2015
- Substantial Net Income Driven by More Than $180 Million in Revenue - 2015 Financial Guidance Significantly Improved - Conference Call Webcast Tuesday, August 4, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Aug. 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported net income of $35.6 million and $18.9 million for the three and six months ended June 30, 2015, respectively, compared to a net loss of $12.1 million and $43.4 million for the same periods ... 
Printer Friendly Version
08/03/15Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia
CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with severe heterozygous familial hypercholesterolemia (severe HeFH) met its primary efficacy endpoint, a statistically significant reduction in LDL-cholesterol after 60 weeks of treatment of once weekly injections of 200 mg of KYNAMRO compared to placebo. LDL-cholesterol reduction was similar to that observed in prev... 
Printer Friendly Version
08/03/15AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases
CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its ant... 
Printer Friendly Version
07/29/15Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Publication highlights the therapeutic potential of volanesorsen to address unmet needs in patients with high apoC-III and triglyceride levels CARLSBAD, Calif. and CAMBRIDGE, Mass., July 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating vol... 
Printer Friendly Version
07/28/15Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
- Webcast scheduled on Tuesday, August 4 at 11:30 a.m. Eastern Time CARLSBAD, Calif., July 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss its second quarter 2015 financial results and report on pipeline and business progress.  Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com.  A webcast replay will be ... 
Printer Friendly Version
07/27/15Isis Pharmaceuticals Reports Data From ISIS-TTR Rx in Patients With Transthyretin Amyloid-Related Cardiomyopathy
Up to 88 percent reduction in transthyretin protein in patients with TTR-related cardiomyopathy observed CARLSBAD, Calif., July 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy that was presented yesterday by Dr. Merrill Benson at the 20th World Congress on Heart Disease (WCHD) in Vancouver, Canada. "I am encouraged by the sa... 
Printer Friendly Version
07/22/15Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
Publication highlights importance of Lp(a) as a risk factor for cardiovascular disease and the therapeutic potential of antisense drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., July 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers with elevated lipoprotein(a) or Lp(a). An accompanying editorial was also publ... 
Printer Friendly Version
07/21/15Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
First therapy designed to directly target the cause of disease Isis Earns $22 Million Milestone Payment from Roche CARLSBAD, Calif., July 21, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD). ISIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein ... 
Printer Friendly Version
07/14/15Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
CARLSBAD, Calif., July 14, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).  To date, Isis has generated more than $120 million in payments from Biogen related to the development of ISIS-SMNRx. CHERISH, a Phase 3 study of ISIS-SMNRx, is a randomized, double-blind, ... 
Printer Friendly Version
07/06/15Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
BOSTON, July 6, 2015 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).  FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis. In a Phase 2 study published in the NEJM in December 2014,... 
Printer Friendly Version
06/30/15Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting
CARLSBAD, Calif., June 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:   Corporate presentation at its 2015 Annual Meeting of Stockholders When:     Tuesday, June 30 at 5:10 p.m. ET / 2:10 p.m. PT Where:     www.isispharm.com  How:        Live on the Internet.  Simply log onto our website listed above. ... 
Printer Friendly Version
06/29/15Isis Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index
CARLSBAD, Calif., June 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has been added to the Russell 1000 Index, effective June 26, 2015. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership. "We are pleased to be added to this impo... 
Printer Friendly Version
06/22/15Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Continued increases observed in multiple measures of muscle function in SMA children treated with ISIS-SMN Rx CARLSBAD, Calif., June 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx  and are continuing to receive treatment in an open-label extension (OLE) study.  Consistent with earlier observations, increases in muscle function... 
Printer Friendly Version
06/16/15Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House
CARLSBAD, Calif., June 16, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2015 Annual Meeting of Stockholders and Open House on Tuesday, June 30 at 2:10 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of May 4, 2015) 2:10 p.... 
Printer Friendly Version
06/11/15Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
Webcast to review study data scheduled for Thursday, June 11 at 8:30 a.m. Eastern Time CARLSBAD, Calif., June 11, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants with Type I spinal muscular atrophy (SMA).  Previously the company reported data from this study on event-free survival, measures of muscle function and assessments of developmental milestones.  The data reported today sh... 
Printer Friendly Version
06/10/15Isis Pharmaceuticals to Host Webcast to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
- Webcast scheduled on Thursday, June 11 at 8:30 a.m. Eastern Time CARLSBAD, Calif., June 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Thursday, June 11 at 8:30 a.m. Eastern Time to discuss data from ISIS-SMNRx Phase 2 study in infants with spinal muscular atrophy.  Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com.  A webcast replay will be available for ... 
Printer Friendly Version
06/05/15Isis Pharmaceuticals' License Agreement With Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval
- Isis to Receive $100 Million Upfront Payment CARLSBAD, Calif., June 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Based on this approval, Bayer will pay Isis an immediate $100 million up-front payment. In total, Isis is eligible to receive up to $375 million in payments, including t... 
Printer Friendly Version
06/04/15Isis Pharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
CARLSBAD, Calif., June 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, 2015 at 2:40 p.m. Pacific Time in Rancho Palos Verdes, CA. A live webcast of the presentation will be available on the "Investors & Media" section of the Isis website.  The replay will be available within 48 hours ... 
Printer Friendly Version
05/28/15Webcast Alert: Akcea Therapeutics Conference Call
CARLSBAD, Calif., May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:    Akcea Therapeutics Webcast When:    Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m. PT Where:   www.isispharm.com How:      Live on the Internet.  Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the we... 
Printer Friendly Version
05/05/15Isis Reports Financial Results and Highlights for First Quarter 2015
- Pro Forma Operating Income Driven by $46 Million in Partner Payments - Conference Call Webcast Tuesday, May 5, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., May 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014.  Isis' significantly improved financial results were due to higher re... 
Printer Friendly Version
05/04/15Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
--Bayer to develop ISIS-FXI Rx broadly for the prevention of thrombosis-- --Transaction maximizes value of the ISIS-FXI Rx program-- --Partnership provides Isis with significant potential to participate in commercial success of ISIS-FXI Rx-- CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombo... 
Printer Friendly Version
04/30/15Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
CARLSBAD, Calif., April 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder.  This is the ninth program to advance, which includes four drugs in development, under Isis' and Biogen's broad strategic alliance to discover and develop novel therapies to treat neurological and neuromuscular disorders.  "Together with B... 
Printer Friendly Version
04/29/15Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call
CARLSBAD, Calif., April 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2015 Financial Results When: Tuesday, May 5 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. ... 
Printer Friendly Version
04/22/15Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Up to 92 percent reduction in transthyretin protein in patients with familial amyloid polyneuropathy CARLSBAD, Calif., April 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx.  An analysis conducted... 
Printer Friendly Version
04/10/15Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., April 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 in New York, NY; 40th Annual Deutsche Bank Health Care Conference on Thursday, May 7, 2015 in Boston, MA; 2015 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 12, 201... 
Printer Friendly Version
03/23/15Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx
CARLSBAD, Calif., March 23, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx.  In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).  In addition, statistically significant reductions from baseline in lipid parameters w... 
Printer Friendly Version
03/06/15Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
CARLSBAD, Calif., March 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $9 million milestone payment from Biogen Idec related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA).  ENDEAR, a Phase 3 study of ISIS-SMNRx, is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA.  The study will evaluate the e... 
Printer Friendly Version
03/02/15Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., March 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  "We are very pleased with the progress we are making with ISIS-TTRRx, and plan to report data from the Phase 2/3 study in 2017.  We have many patients who have completed the fifteen months of dosing and are now recei... 
Printer Friendly Version
02/27/15Isis Reports Financial Results and Highlights for 2014
- Isis Outperforms 2014 Projections for Pro Forma Net Operating Loss and Year-end Cash - Isis Achieves Profitable Fourth Quarter - More than $230 Million in Payments from Partners Drives Significantly Improved Financial Results - Conference Call Webcast Friday, February 27, 10:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL... 
Printer Friendly Version
02/24/15ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
CARLSBAD, Calif., Feb. 24, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx.  In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).  HAE is a severe and rare genetic disease that is ... 
Printer Friendly Version
02/20/15Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call
CARLSBAD, Calif., Feb. 20, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:        Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call When:    Friday, February 27 at 10:30 a.m. ET / 7:30 a.m. PT Where:     www.isispharm.com How:       Live on the Internet.  Simply log onto our website... 
Printer Friendly Version
02/10/15Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
CARLSBAD, Calif., Feb. 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders.  Isis will continue to evaluate the target with the goal of advancing this program into development.  "Together with... 
Printer Friendly Version
02/05/15Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
--Fourth Drug to Enter Development Under Broad Strategic Collaboration CARLSBAD, Calif., Feb. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4Rx.  ISIS-BIIB4Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.  ISIS-BIIB4Rx is the fourt... 
Printer Friendly Version
02/04/15Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at: 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 in New York, NY; Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 in Boston, MA; and 27th Annual ROTH Conference on Monday, March 9, 2015 in Laguna Niguel. The above listed dates are s... 
Printer Friendly Version
02/03/15Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes
CARLSBAD, Calif., Feb. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in patients with type 2 diabetes.  In the Phase 2 study patients treated with ISIS-PTP1BRx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).  In patients treated with ISIS-PTP1BRx, a mean reduction in HbA1c of 0.7 percentage points from baseline was achieved at 36 weeks, compared to a mean reduction o... 
Printer Friendly Version
01/14/15Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
CARLSBAD, Calif., Jan. 14, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).  The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies.  In this study, children with SMA are receiving a 12 ... 
Printer Friendly Version
01/09/15Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
New Agreement Includes Cross-License on Four Disease Targets, Providing Each Company Exclusive RNA Therapeutic License Rights for Two Programs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in ... 
Printer Friendly Version
01/08/15Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance
Strong Performance represents success of novel business strategy CARLSBAD, Calif., Jan. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Company expects to significantly improve upon its 2014 financial guidance.  The Company expects to end 2014 with a pro forma net operating loss (NOL) in the mid to high teens and more than $725 million in cash.  The significantly improved financial performance of the Company in 2014 was a result of the successful exe... 
Printer Friendly Version
01/06/15Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the appointment of Paula Soteropoulos as president and chief executive officer (CEO) of Akcea Therapeutics, the Isis-owned, lipid franchise subsidiary responsible for the development and commercialization of Isis' lipid drugs, ISIS-APOCIIIRx, ISIS-APO(a)Rx, ISIS-A... 
Printer Friendly Version
01/05/15Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
Isis Strengthens Management Team Adding Strategic Business and Strategic Marketing Expertise CARLSBAD, Calif., Jan. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Sarah Boyce has joined the company as chief business officer.  In this newly created position, Ms. Boyce will provide strategic leadership from a commercial background and lead Isis' corporate development activities, including corporate communications, business development, patient advocacy, c... 
Printer Friendly Version
01/05/15Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation -- CARLSBAD, Calif., Jan. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract.  The collaboration brings together Isis' RNA-targeted t... 
Printer Friendly Version
01/02/15Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 2:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis w... 
Printer Friendly Version